Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 67, Issue 5, 2002, Pages 333-339

  Chehne, Fahdi ^a,d   Oguogho, Anthony ^a,e   Lupattelli, G ^b   Palumbo, B ^b   Sinzinger, Helmut ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^d UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

^e AMBROSE ALLI UNIVERSITY   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ISOPROSTANE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OXIDATION; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; URINE; VASCULAR DISEASE; VASCULAR TISSUE;

EID: 0036855531     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2002.0438     Document Type: Article

References (22)

1. Krupski W. C. The peripheral vascular consequence of smoking. Ann Vasc Surg 1991; 5: 91-95.
2. Miettinen O. S., Neff R. K., Jick H. Cigarette smoking and nonfatal myocardial infarction: Rate ratio in relation to age, sex and predisposing conditions. Am J Epidemiol 1976; 103: 30-36.
3. Scheffler E., Wiest E., Woehrle J., Otto I., Schulz I., Huber L. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest 1992; 70: 263-265.
4. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol; modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924
5. 2-isoprostanes during oxidative modification of low-density lipoprotein. Biochem Biophys Res Commun 1994; 200: 338-343
6. 2α in heterozygous hypercholesterolemia. Wr Klin Wschr 1999; 111: 113-118.
7. 2α in the arterial wall layers of various species - A comparison between intact and atherosclerotic arteries. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 167-171.
8. Sinzinger H., Oguogho A., Kritz H., Pirich C., Wagner O., Mehrabi M., Peskar B. A. Isoprostanes in atherosclerotic lesions. Atherosclerosis 1997; 134: 276.
9. 2α in human atherosclerotic vascular tissue. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 129-134.
10. Reilly M. P., Delanty N., Lawson J. A., FitzGerald G. A. Modulation of oxidant stress in-vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25.
11. Sinzinger H., Oguogho A., Meghdadi S., Kritz H., Schmid P. Quitting smoking immediately improves in vivo oxidation injury. Eur Heart J 1999; 20: 659.
12. 2α is accumulated in coronary arteries isolated from patients with coronary heart disease. J Cardiovasc Res 1999; 43: 492-499.
13. Morrow J. D., Robert II L. J. The isoprostanes: Current knowledge and direction of future research. Biochem Pharmacol 1996; 51: 1-9.
14. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. New Engl J Med 1995; 332: 1198-1203.
15. 2α: An index of oxidative stress in vivo. Circulation 1996; 94: 277.
16. 2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999; 61: 203-205.
17. Arakil Aghajanian A., Oguogho A., Sinzinger H. Isoprostane, eine neue substanzgruppe in der angiologie - In der zukunft von bedeutung? VASA 1997; 26: 65-69
18. 2) biosynthesis in arteries. Artery 1980; 7: 477-495
19. 2α. Br J Pharm 1996; 119: 1276-1280.
20. 2-isoprostane. Biochem Biophys Res Commun 1993; 195: 507-515.
21. 2-isoprostane, on endothelin-1 release. J Cardiovasc Pharm 1995; 26: 51-52.
22. Leitinger N., Blazek I., Sinzinger H. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets. Thromb Res 1997; 86: 337-342.